These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20160358)

  • 41. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.
    Caponetti GC; Dave BJ; Perry AM; Smith LM; Jain S; Meyer PN; Bast M; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Aoun P; Fu K; Greiner TC; Chan WC; Sanger WG; Weisenburger DD
    Leuk Lymphoma; 2015; 56(11):3082-9. PubMed ID: 25827211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
    Vitolo U; Botto B; Capello D; Vivenza D; Zagonel V; Gloghini A; Novero D; Parvis G; Calvi R; Ariatti C; Milan I; Bertini M; Boccomini C; Freilone R; Pregno P; Orsucci L; Palestro G; Saglio G; Carbone A; Gallo E; Gaidano G
    Leukemia; 2002 Feb; 16(2):268-75. PubMed ID: 11840294
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Large B-cell lymphoma with Hodgkin's features.
    García JF; Mollejo M; Fraga M; Forteza J; Muniesa JA; Pérez-Guillermo M; Pérez-Seoane C; Rivera T; Ortega P; Piris MA
    Histopathology; 2005 Jul; 47(1):101-10. PubMed ID: 15982329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
    Shim H; Oh JI; Park SH; Jang S; Park CJ; Huh J; Suh C; Chi HS
    J Clin Pathol; 2013 May; 66(5):420-5. PubMed ID: 23610041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology.
    Winter JN
    Curr Hematol Malig Rep; 2007 Oct; 2(4):235-41. PubMed ID: 20425375
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations.
    Horn H; Staiger AM; Vöhringer M; Hay U; Campo E; Rosenwald A; Ott G; Ott MM
    Am J Surg Pathol; 2015 Jan; 39(1):61-6. PubMed ID: 25229766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of chromosomal translocations in small-bowel diffuse large B-cell lymphoma.
    Ikegami K; Nakamura S; Esaki M; Yanai S; Hirahashi M; Oda Y; Takeshita M; Matsumoto T; Kitazono T
    Histopathology; 2016 Jan; 68(2):199-209. PubMed ID: 25953462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
    Oki Y; Noorani M; Lin P; Davis RE; Neelapu SS; Ma L; Ahmed M; Rodriguez MA; Hagemeister FB; Fowler N; Wang M; Fanale MA; Nastoupil L; Samaniego F; Lee HJ; Dabaja BS; Pinnix CC; Medeiros LJ; Nieto Y; Khouri I; Kwak LW; Turturro F; Romaguera JE; Fayad LE; Westin JR
    Br J Haematol; 2014 Sep; 166(6):891-901. PubMed ID: 24943107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA signatures in subtypes of follicular lymphoma.
    Gebauer N; Gollub W; Stassek B; Bernard V; Rades D; Feller AC; Thorns C
    Anticancer Res; 2014 May; 34(5):2105-11. PubMed ID: 24778012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma.
    Chan A; Dogan A
    Surg Pathol Clin; 2019 Sep; 12(3):699-707. PubMed ID: 31352982
    [No Abstract]   [Full Text] [Related]  

  • 54. Double hit lymphoma: from biology to therapeutic implications.
    Burotto M; Berkovits A; Dunleavy K
    Expert Rev Hematol; 2016 Jul; 9(7):669-78. PubMed ID: 27166590
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry.
    Tomita N; Takeuchi K; Hyo R; Hashimoto C; Takemura S; Taguchi J; Fujita H; Fujisawa S; Ogawa K; Motomura S; Ishigatsubo Y
    Acta Haematol; 2009; 121(4):196-201. PubMed ID: 19468204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
    Fiskvik I; Beiske K; Delabie J; Yri O; Spetalen S; Karjalainen-Lindsberg ML; Leppä S; Liestøl K; Smeland EB; Holte H
    Leuk Lymphoma; 2015 Jun; 56(6):1742-9. PubMed ID: 25284491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
    Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
    APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome.
    Pedersen MØ; Gang AO; Clasen-Linde E; Breinholt MF; Knudsen H; Nielsen SL; Poulsen TS; Klausen TW; Høgdall E; Nørgaard P
    Eur J Haematol; 2019 May; 102(5):395-406. PubMed ID: 30737994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
    Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
    Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.
    Li M; Liu Y; Wang Y; Chen G; Chen Q; Xiao H; Liu F; Qi C; Yu Z; Li X; Fan L; Guo Y; Yan Q; Guo S; Wang Z
    Am J Surg Pathol; 2017 Oct; 41(10):1322-1332. PubMed ID: 28319526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.